Documentation
Peptide modifications explained
Many research peptides are not a plain chain of the twenty standard amino acids. Terminal caps, non-natural residues, ring closures and attached groups all change the expected mass, and many change how the peptide behaves in the lab.
Why modifications matter when you check a batch
A modification changes the molecular formula, so it changes the mass you should expect in a mass spectrum. It can also change net charge, hydrophobicity, HPLC retention time and solubility. When you compare a COA with your order, check that the sequence notation includes every modification you expect, and that the measured mass matches a calculation that includes them. See Peptide purity: HPLC and mass spectrometry explained.
Common modifications at a glance
Mass changes below are monoisotopic and are relative to the unmodified peptide.
| Modification | Typical notation | Mass change | Main effects |
|---|---|---|---|
| C-terminal amidation | …-NH2 (e.g. …-Gly-NH2) | −0.984 Da | Removes the C-terminal negative charge |
| N-terminal acetylation | Ac-… (e.g. Ac-Ala-…) | +42.011 Da | Removes the N-terminal positive charge; slightly more hydrophobic |
| D-amino acid | D-Ala, or lower-case one-letter code (a) | None | Can change conformation and resistance to proteases in vitro; HPLC retention may shift |
| Disulfide bridge | "Disulfide bridge: Cys2–Cys7", or a connecting line in a structure drawing | −2.016 Da per bridge | Constrains conformation; free thiols no longer present |
| Head-to-tail cyclisation (amide bond) | cyclo(…) | −18.011 Da | Both terminal charges removed; conformation constrained |
| N-terminal pyroglutamate | pGlu-… or Pyr-… | −17.027 Da from Gln; −18.011 Da from Glu | N-terminal charge removed; can also form unintentionally from N-terminal Gln |
| Phosphorylation | pSer, pThr, pTyr, or Ser(PO3H2) | +79.966 Da per group | Adds negative charge; often lowers HPLC retention |
| PEGylation | PEG chain named by length or average mass (e.g. PEG4, PEG 2 kDa) | +44.026 Da per ethylene glycol unit | More hydrophilic; larger hydrodynamic size |
| Palmitoylation (C16 lipid) | Pal-, or Lys(Pal) | +238.230 Da | Much more hydrophobic; prone to aggregation and adsorption |
| Biotin label | Biotin-…, or Lys(Biotin) | +226.078 Da | Enables streptavidin-based capture and detection |
| Carboxyfluorescein (FAM) label | 5-FAM-…, 5(6)-FAM-… | +358.048 Da | Fluorescent; light-sensitive |
| Fluorescein isothiocyanate (FITC) label | FITC-… | +389.036 Da | Fluorescent; light-sensitive |
Terminal modifications
C-terminal amidation replaces the C-terminal carboxyl group with a carboxamide. Many naturally occurring peptides are amidated, and synthetic versions are made on resins that release the amide directly. The mass difference from the free acid is under 1 Da, so a low-resolution spectrum may not distinguish the two clearly; the notation on the COA and a correctly calculated mass are the best checks.
N-terminal acetylation caps the N-terminal amine. Together with amidation, it is often used to make a short synthetic peptide resemble the same segment within a longer protein, where the ends are not charged. Both caps change the net charge, which affects solubility and the choice of solvent. See Dissolving peptides for in-vitro assays.
D-amino acids and other non-standard residues
A D-amino acid has the same formula as its L-form, so the mass spectrum cannot confirm it. Confirming stereochemistry needs a method that separates enantiomers, such as chiral chromatography after hydrolysis. Other non-standard residues, such as norleucine, ornithine or aminohexanoic acid (Ahx, often used as a spacer, +113.084 Da), are usually written with three-letter or bracketed abbreviations; check the supplier's key if an abbreviation is unfamiliar.
Disulfide bridges and cyclisation
A disulfide bridge forms when two cysteine thiols are oxidised, losing two hydrogen atoms (−2.016 Da). Peptides with more than one bridge can form different pairings with the same mass, so the documentation should state which cysteines are linked and how this was confirmed. A sample of a disulfide-bridged peptide that shows a mass about 2 Da higher than expected per bridge may contain the reduced form.
Head-to-tail cyclisation forms an amide bond between the N- and C-termini, with the loss of one water molecule (−18.011 Da). Side chain-to-side chain lactam bridges, for example between lysine and aspartic or glutamic acid side chains, involve the same loss of water.
PEGylation and lipidation
Polyethylene glycol (PEG) chains come in two forms. Discrete PEGs, with a defined number of ethylene glycol units, add a single defined mass. Conventional polymeric PEGs are polydisperse: the mass spectrum shows a distribution of peaks spaced 44 Da apart rather than one peak, and the documentation should quote an average mass.
Lipidation attaches a fatty acid, usually to the N-terminus or to a lysine side chain. Lipidated peptides are markedly more hydrophobic: they elute much later in reversed-phase HPLC, often need an organic co-solvent to dissolve, and can stick to plastic and glass surfaces.
Labels
Biotin and fluorescent labels are usually attached at the N-terminus or to a lysine side chain, often through a spacer such as Ahx to reduce interference between the label and the peptide. An N-terminal FITC label attached directly to the peptide can be lost during acidic cleavage from the synthesis resin, which is one reason a spacer is commonly used. Fluorescent peptides should be stored and handled protected from light.
How modifications appear on a spec sheet
- Sequence line: modifications written into the sequence, such as Ac-, -NH2, Lys(Biotin) or cyclo(…).
- Bridge or cyclisation statement: which residues are linked.
- Molecular formula and molecular weight: these should include every modification. A quick check is to compare them with the value calculated for the unmodified sequence plus the mass changes above.
- MS result: the observed mass should match the modified, not the unmodified, peptide.
Related: How to read a peptide Certificate of Analysis and Common impurities in synthetic peptides.
Further reading
- N- and C-terminal modifications and mass spectrometry
- PTMs and glycoprotein mass spectrometry, with HCG
Sources and further reading
- Unimod: protein modifications for mass spectrometry (unimod.org), for monoisotopic mass changes of common modifications.
- Chan WC, White PD (eds). Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford University Press; 2000.
- United States Pharmacopeia, General Chapter <1503> Quality Attributes of Synthetic Peptide Drug Substances.
Frequently asked questions
How much does C-terminal amidation change the mass?
-0.984 Da relative to the free acid, which a low-resolution spectrum may not resolve; the COA notation and a correctly calculated mass are the best checks.
What does N-terminal acetylation change?
+42.011 Da, and it removes the N-terminal positive charge.
Does a D-amino acid change the mass?
No. It has the same mass but can change conformation, protease resistance and HPLC retention.
Why do modifications matter when checking a batch?
They change the formula, so the expected mass, and they can change charge, hydrophobicity, retention time and solubility. The measured mass should match a calculation that includes every modification.